Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Longitudinal progression of aspirin-exacerbated respiratory disease: analysis of a national insurance claims database.

Roland LT, Wang H, Mehta CC, Cahill KN, Laidlaw TM, DelGaudio JM, Wise SK, Levy JM.

Int Forum Allergy Rhinol. 2019 Aug 23. doi: 10.1002/alr.22412. [Epub ahead of print]

PMID:
31442000
2.

Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial.

Cahill KN, Cui J, Kothari P, Murphy K, Raby BA, Singer J, Israel E, Boyce JA, Laidlaw TM.

Am J Respir Crit Care Med. 2019 Sep 15;200(6):704-711. doi: 10.1164/rccm.201809-1755OC.

PMID:
30978291
3.

Sinus surgery improves lower respiratory tract reactivity during aspirin desensitization for AERD.

Huang GX, Palumbo ML, Singer JI, Cahill KN, Laidlaw TM.

J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1647-1649. doi: 10.1016/j.jaip.2019.02.037. Epub 2019 Mar 12. No abstract available.

PMID:
30877073
4.

Hearing loss and middle ear symptoms in aspirin-exacerbated respiratory disease.

Mullur J, Singer J, Roditi R, Cahill KN.

J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1671-1672.e3. doi: 10.1016/j.jaip.2018.11.034. Epub 2018 Dec 8. No abstract available.

PMID:
30529603
5.

A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease.

DeGregorio GA, Singer J, Cahill KN, Laidlaw T.

J Allergy Clin Immunol Pract. 2019 Apr;7(4):1174-1180. doi: 10.1016/j.jaip.2018.10.032. Epub 2018 Nov 2.

PMID:
30391549
6.

Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease.

Cahill KN, Murphy K, Singer J, Israel E, Boyce JA, Laidlaw TM.

J Allergy Clin Immunol. 2019 Feb;143(2):799-803.e2. doi: 10.1016/j.jaci.2018.10.007. Epub 2018 Oct 16. No abstract available.

7.

A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease.

Eid RC, Palumbo ML, Laidlaw TM, Buchheit KM, Cahill KN.

J Allergy Clin Immunol Pract. 2019 Apr;7(4):1338-1340. doi: 10.1016/j.jaip.2018.09.012. Epub 2018 Sep 25. No abstract available.

PMID:
30261317
8.

Allergic inflammatory memory in human respiratory epithelial progenitor cells.

Ordovas-Montanes J, Dwyer DF, Nyquist SK, Buchheit KM, Vukovic M, Deb C, Wadsworth MH 2nd, Hughes TK, Kazer SW, Yoshimoto E, Cahill KN, Bhattacharyya N, Katz HR, Berger B, Laidlaw TM, Boyce JA, Barrett NA, Shalek AK.

Nature. 2018 Aug;560(7720):649-654. doi: 10.1038/s41586-018-0449-8. Epub 2018 Aug 22.

9.

A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease.

Laidlaw TM, Cahill KN, Cardet JC, Murphy K, Cui J, Dioneda B, Kothari P, Raby BA, Israel E, Boyce JA.

J Allergy Clin Immunol. 2019 Jan;143(1):316-324.e7. doi: 10.1016/j.jaci.2018.06.001. Epub 2018 Jun 8.

PMID:
29890239
10.

A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease.

Tuttle KL, Buchheit KM, Laidlaw TM, Cahill KN.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):1045-1047. doi: 10.1016/j.jaip.2018.01.038. Epub 2018 Mar 6. No abstract available.

11.

Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial.

Schneider TR, Johns CB, Palumbo ML, Murphy KC, Cahill KN, Laidlaw TM.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):825-831. doi: 10.1016/j.jaip.2017.10.011. Epub 2017 Nov 10.

12.

Novel Treatments for Airway Disease.

Cahill KN, Boyce JA, Israel E.

N Engl J Med. 2017 Aug 10;377(6):597. doi: 10.1056/NEJMc1708004. No abstract available.

PMID:
28813135
13.

KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma.

Cahill KN, Katz HR, Cui J, Lai J, Kazani S, Crosby-Thompson A, Garofalo D, Castro M, Jarjour N, DiMango E, Erzurum S, Trevor JL, Shenoy K, Chinchilli VM, Wechsler ME, Laidlaw TM, Boyce JA, Israel E.

N Engl J Med. 2017 May 18;376(20):1911-1920. doi: 10.1056/NEJMoa1613125.

14.

Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs.

Laidlaw TM, Cahill KN.

J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):537-545. doi: 10.1016/j.jaip.2016.10.021. Review.

PMID:
28483309
15.

Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease.

Cahill KN, Boyce JA.

J Allergy Clin Immunol. 2017 Mar;139(3):764-766. doi: 10.1016/j.jaci.2016.09.025. Epub 2016 Oct 19. No abstract available.

PMID:
27771324
16.

Pathogenesis of Aspirin-Induced Reactions in Aspirin-Exacerbated Respiratory Disease.

Cahill KN, Laidlaw TM.

Immunol Allergy Clin North Am. 2016 Nov;36(4):681-691. doi: 10.1016/j.iac.2016.06.005. Epub 2016 Sep 13. Review.

PMID:
27712763
17.

Automated identification of an aspirin-exacerbated respiratory disease cohort.

Cahill KN, Johns CB, Cui J, Wickner P, Bates DW, Laidlaw TM, Beeler PE.

J Allergy Clin Immunol. 2017 Mar;139(3):819-825.e6. doi: 10.1016/j.jaci.2016.05.048. Epub 2016 Jul 25.

18.

Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease.

Shah NH, Schneider TR, DeFaria Yeh D, Cahill KN, Laidlaw TM.

J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1215-1219. doi: 10.1016/j.jaip.2016.04.028. Epub 2016 Jul 7.

19.

Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.

Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, Lai J, Bhattacharyya N, Israel E, Boyce JA, Laidlaw TM.

J Allergy Clin Immunol. 2016 May;137(5):1566-1576.e5. doi: 10.1016/j.jaci.2015.10.020. Epub 2015 Dec 12.

20.

Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Stevens W, Buchheit K, Cahill KN.

Curr Allergy Asthma Rep. 2015 Dec;15(12):69. doi: 10.1007/s11882-015-0569-2. Review.

PMID:
26475526
21.

Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease.

Cahill KN, Raby BA, Zhou X, Guo F, Thibault D, Baccarelli A, Byun HM, Bhattacharyya N, Steinke JW, Boyce JA, Laidlaw TM.

Am J Respir Cell Mol Biol. 2016 Jan;54(1):34-40. doi: 10.1165/rcmb.2014-0486OC.

22.

Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease.

Lee-Sarwar K, Johns C, Laidlaw TM, Cahill KN.

J Allergy Clin Immunol Pract. 2015 May-Jun;3(3):449-51. doi: 10.1016/j.jaip.2015.01.007. Epub 2015 Jan 26. No abstract available.

23.

Aspirin exacerbated respiratory disease: the search for a biomarker.

Cahill KN, Laidlaw TM.

Ann Allergy Asthma Immunol. 2014 Nov;113(5):500-1. doi: 10.1016/j.anai.2014.08.017. Epub 2014 Nov 5. No abstract available.

PMID:
25442693
24.

Prostaglandin Dâ‚‚: a dominant mediator of aspirin-exacerbated respiratory disease.

Cahill KN, Bensko JC, Boyce JA, Laidlaw TM.

J Allergy Clin Immunol. 2015 Jan;135(1):245-52. doi: 10.1016/j.jaci.2014.07.031. Epub 2014 Sep 11.

25.

Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies.

Hong DI, Bankova L, Cahill KN, Kyin T, Castells MC.

Expert Rev Clin Immunol. 2012 Jan;8(1):43-52; quiz 53-4. doi: 10.1586/eci.11.75. Review.

PMID:
22149339
26.
27.

Emissions pathways, climate change, and impacts on California.

Hayhoe K, Cayan D, Field CB, Frumhoff PC, Maurer EP, Miller NL, Moser SC, Schneider SH, Cahill KN, Cleland EE, Dale L, Drapek R, Hanemann RM, Kalkstein LS, Lenihan J, Lunch CK, Neilson RP, Sheridan SC, Verville JH.

Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12422-7. Epub 2004 Aug 16.

Supplemental Content

Loading ...
Support Center